A A A

Eye Therapy News

Professor Ali honoured for his contribution to research into retinal disease

Mon, 08 Sep 2014 12:27:36 +0000

              Professor Robin Ali, PhD, Professor of Human Molecular Genetics and Head of the Department of Genetics, UCL Institute of Opthalmology has been awarded the Pioneer Award for his work in proof-of-concept studies that have demonstrated the feasibility of using gene therapy and cell transplantation to treat dysfunction and degeneration of the cells […]

Read more...

Achromatopsia might not be as progressive as previously thought

Mon, 08 Sep 2014 11:17:16 +0000

A recent publication from the UCL Institute of Ophthalmology, Moorfields Eye Hospital, and the Medical College of Wisconsin indicates that for the majority of people with achromatopsia, the condition may not be as progressive as previously suggested. Data from this study by Aboshiha et al. demonstrated that for the majority of people with achromatopsia (a […]

Read more...

2 Lazy 2 Run? We’re biking it for blood cancer!

Fri, 29 Aug 2014 09:30:05 +0000

  On Sunday 31 August a group of not so elite athletes from the Gene and Cell Therapy group will be taking part in the London Bikeathon 2014 to raise funds for Leukaemia & Lymphoma Research. The 2 Lazy 2 Run CC will be cycling 52 miles – that’s more than a marathon, no mean feet […]

Read more...

The Art of Eyes

Thu, 07 Aug 2014 14:23:19 +0000

The eye is an object of great beauty as shown by the Ophthalmologist in their July/August 2014 issue. This month’s issue features a photo essay called The Art of the Eyes and includes examples of the work from a number research labs capturing the complex and beautiful detail of the eye and its cells. The essay includes images […]

Read more...

In memoriam

Tue, 05 Aug 2014 16:02:34 +0000

Dr Yoshiki Sasai (1962 – 2014) It is with great sadness today that we remember and pay tribute to our collaborator Dr Yoshiki Sasai. Yoshiki was a world leading stem cell researcher and Deputy Director of the Riken Center for Developmental Biology in Kobe, Japan. Through his hard work and dedication over many years, Yoshiki […]

Read more...

Europe's first safety trial investigating transplantation of stem cell-derived retinal cells in Stargardt disease begins

28 May 2012

We have started a clinical trial to assess the safety of injecting retinal pigment epithelium (RPE) cells, grown from embryonic stem (ES) cells, into the eyes of patients with Stargardt macular dystrophy. This is the first clinical trial in Europe to use cells derived from ES cells, and follows an ongoing study in the USA where two patients received similar cells without any complications to date.

Beginning with patients that are severely visually impaired and designed to test whether the transplants are safe, this trial uses RPE cells that have been turned into RPE cells in a dish - it is the mature RPE cells that are injected, in the hope that they can repair the damaged tissue safely.

So far four patients have undergone the surgery, which went smoothly, and they will be followed over the next two years to ensure the technique is well-tolerated.

Further studies would be required to determine whether vision can also be improved.

People with Stargardt macular dystrophy may be eligible to participate in this trial and in future studies if they have severe sight loss sue to Stargardt and are otherwise well. For further information, please contact us.

Page last modified on 28 may 12 08:56